We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA REVISES GUIDANCE ON BOTANICAL DRUG PRODUCTS
FDA REVISES GUIDANCE ON BOTANICAL DRUG PRODUCTS
June 8, 2004
The FDA has released a revised guidance document spelling out when new drug applications (NDAs) for the marketing of botanical drug products are required and when such a product can be marketed under an OTC drug monograph.